Novo Nordisk presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver Meeting 2025, in Washington, D.C., evaluating the effects… read more.
MetaVia Inc a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that an abstract highlighting data on Vanoglipel (DA-1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, has… read more.
Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third of the adult population. This disorder is characterized by the… read more.
Americans who drink heavily are more than twice as likely to develop significant liver disease compared to 20 years ago, according to a new Keck Medicine of USC study published today… read more.
The type 2 diabetes treatment dapagliflozin appears to also benefit patients with liver disease, researcher reported on June 4, 2025 in The BMJ today. The findings suggest that treatment with… read more.
Results from a large, retrospective Swedish study indicate that people with fatty liver disease have almost twice the risk of death in a 5-7 year period when compared… read more.
Ipsen announced late-breaking data for Iqirvo (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American… read more.
GSK plc (will present 12 abstracts at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2024, taking place in San Diego, CA from 15-19… read more.
Mirum Pharmaceuticals, Inc. (announced that it will present data at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting®, taking place November 15-19, 2024,… read more.
As described in research published in the Biotechnology Journal, investigators have developed a novel patch that can help liver tissue regenerate. The patch is a combination of decellularized liver… read more.
Metabolic (bariatric) surgery is more effective than medications and lifestyle interventions for the treatment of advanced non-alcoholic fatty liver disease. A new paper, published today in The Lancet… read more.
Obesity can give rise to a variety of health concerns. Nonalcoholic steatohepatitis (NASH)—a type of fatty liver disease that might progress to cancer—is particularly prevalent among obese people…. read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
